CN113975653A - Phototherapy device for relieving leucoderma symptoms - Google Patents
Phototherapy device for relieving leucoderma symptoms Download PDFInfo
- Publication number
- CN113975653A CN113975653A CN202111494379.2A CN202111494379A CN113975653A CN 113975653 A CN113975653 A CN 113975653A CN 202111494379 A CN202111494379 A CN 202111494379A CN 113975653 A CN113975653 A CN 113975653A
- Authority
- CN
- China
- Prior art keywords
- cavity
- phototherapy
- lead
- symptoms
- vitiligo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001126 phototherapy Methods 0.000 title claims abstract description 112
- 208000024891 symptom Diseases 0.000 title claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 35
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 29
- 238000002955 isolation Methods 0.000 claims abstract description 29
- 230000007480 spreading Effects 0.000 claims abstract description 26
- 238000003892 spreading Methods 0.000 claims abstract description 26
- 239000000758 substrate Substances 0.000 claims abstract description 15
- 238000001514 detection method Methods 0.000 claims description 21
- 239000006185 dispersion Substances 0.000 claims description 17
- 238000009792 diffusion process Methods 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 12
- 230000006835 compression Effects 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 238000013461 design Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 210000002752 melanocyte Anatomy 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040825 Skin depigmentation Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000005574 cross-species transmission Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0616—Skin treatment other than tanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0664—Details
Landscapes
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
The application discloses a phototherapy device for alleviating vitiligo symptom includes: a substrate; a first cavity is formed on the first side of the substrate, and a first phototherapy module is formed in the first cavity; two second cavities are formed on the first side of the substrate and distributed on two sides of the first cavity; the second cavity is provided with accommodating parts capable of accommodating liquid medicine, and transparent isolating parts respectively communicated with the accommodating parts are arranged between the two accommodating parts; the transparent isolation part is laid on the first phototherapy module; and one side of the transparent isolation layer, which is relatively far away from the first phototherapy module, is provided with spreading holes.
Description
Technical Field
The present disclosure relates generally to the field of photomedical technology, and more particularly to a phototherapy device for alleviating symptoms of vitiligo.
Background
Vitiligo is a common acquired depigmentation skin disease, and is manifested by limitation or generalized. The melanocyte function of skin is lost or the number of cells is reduced, and the melanocyte function is usually found on the head, face, extremities, back, friction area, and the interface between skin and mucous membrane. The etiology of the leucoderma is not completely clear, and the leucoderma can be treated by drug therapy, pigment transplantation, phototherapy, decoloration therapy and the like, wherein the treatment is mainly used for relieving symptoms, and the leucoderma cannot be completely cured.
The incidence rate tends to rise in the last decade, the vitiligo does not endanger life but seriously affects beauty, and the heterogeneous eye light around the patient causes serious psychological burden to the patient, and affects job hunting and friend making. In the prior art, ultraviolet laser obtains good curative effect in treating limited vitiligo, and has the main advantages of less treatment times, but the adopted ultraviolet laser therapeutic apparatus has the problems of large volume, short service life, low efficiency, high-pressure excitation, inconvenient use and the like, large-area treatment cannot be carried out, and high energy of the ultraviolet laser therapeutic apparatus can cause certain damage to skin and has certain side effect.
In order to solve the above technical problems, patent ZL201610789719.7 also provides an OLED vitiligo treatment apparatus, which uses OLEDs as a treatment light source, and uses red light emitted by a red light emitting unit to cooperate with a repair paste to effectively stimulate melanocytes to secrete melanin, reduce the concentration level of hydrogen peroxide in vitiligo skin, and further treat vitiligo. Although the technical scheme solves the technical problems to a certain extent, in practical application, the leucoderma treatment end cannot realize self-administration, and needs to be improved.
Disclosure of Invention
In view of the above-mentioned drawbacks and deficiencies of the prior art, it would be desirable to provide a phototherapy device for alleviating vitiligo symptoms that enables self-administration compared to the prior art.
A phototherapy device for alleviating symptoms of vitiligo, comprising: a substrate; a first cavity is formed on the first side of the substrate, and a first phototherapy module is formed in the first cavity; two second cavities are formed on the first side of the substrate and distributed on two sides of the first cavity; the second cavity is provided with accommodating parts capable of accommodating liquid medicine, and transparent isolating parts respectively communicated with the accommodating parts are arranged between the two accommodating parts; the transparent isolation part is laid on the first phototherapy module; and one side of the transparent isolation layer, which is relatively far away from the first phototherapy module, is provided with spreading holes.
According to the technical scheme provided by the embodiment of the application, an outlet is arranged on the accommodating part, and a quantitative administration part is arranged at the outlet; the outlet of the quantitative dosing part is connected with the inlet of the transparent isolating part; the accommodating part is also provided with an injection port exposed outside the second cavity.
According to the technical scheme provided by the embodiment of the application, a first cavity is arranged inside the transparent isolation part; the first cavity includes: the overflow and scattering cavity is arranged at two ends of the transparent isolation part and can be communicated with the containing part, and the spreading cavity is positioned in the middle of the overflow and scattering cavity and is communicated with the overflow and scattering cavity; one side of the scattering cavity relatively far away from the first phototherapy module is provided with scattering holes.
According to the technical scheme provided by the embodiment of the application, the overflow dispersion cavity comprises: a liquid-introducing portion communicating with the accommodating portion and a diffusing portion communicating with the liquid-introducing portion; the diameter of the diffusion part is larger than that of the liquid-introducing part.
According to the technical scheme provided by the embodiment of the application, the elastic compression part is arranged at the bottom in the spreading cavity; and the elastic compression part is hollow and communicated with the diffusion part.
According to the technical scheme provided by the embodiment of the application, the region on the same side of the transparent isolation part and the spreading hole is also provided with a leakage-proof region which is annularly arranged on the outer circumferential direction of the spreading cavity; the leakage preventing section includes: the leakage-proof edge is annularly arranged on the circumferential direction of the spreading cavity, and the material of one side of the leakage-proof edge, which faces the spreading cavity, is the same as that of the spreading cavity; and an adsorption layer is arranged on one side of the leakage-proof edge of the bottom edge, which is far away from the spreading cavity.
According to the technical scheme provided by the embodiment of the application, a first space is formed between the first phototherapy module and the circumferential side wall of the first cavity; an elastic expansion part which is arranged annularly is arranged in the first space; the base body is provided with an adjusting part for adjusting the elastic telescopic part and a lead part for connecting the adjusting part and the elastic telescopic part; the adjusting part is rotated to drive the lead part to pull the elastic expansion part to contract or expand.
According to the technical scheme provided by the embodiment of the application, a plurality of first lead channels are arranged on the elastic expansion part in an annular array manner; the base body is provided with a second lead channel which is arranged corresponding to the first lead channel and is communicated with the first lead channel; the other end of the second lead channel is exposed at the second side of the base body; the lead portion includes: the lead enters the first lead channel from the second lead channel and is connected with the inner edge of the elastic adjusting part; the adjusting portion includes: and the retraction mechanism is positioned on the second side of the base body and is used for retracting each lead in the second lead channel.
According to the technical scheme provided by the embodiment of the application, the first phototherapy module comprises: at least one annular phototherapy unit arranged concentrically.
According to the technical scheme provided by the embodiment of the application, an elastic marking ring is arranged between the annular inner edges of the elastic telescopic parts; a detection sensor for detecting the marking ring is arranged between two adjacent phototherapy units; further comprising: a control module configured to drive the phototherapy unit corresponding to the marker ring to be turned off when the detection sensor detects the marker ring.
In summary, the present application discloses a phototherapy device for alleviating vitiligo symptoms, which, on one hand, embeds a first phototherapy module in a first cavity, and after the first phototherapy module is started, can perform phototherapy on the affected part of a patient; on the other hand, second cavities are arranged on two sides of the first cavity, accommodating parts for accommodating liquid medicine are arranged in the two second cavities, and a transparent isolating part communicated with the accommodating parts is arranged between the two accommodating parts. Based on the design, the transparent isolation part is laid on the first phototherapy module; and one side of the transparent isolation part relatively far away from the first phototherapy module is provided with a spreading hole. When the liquid medicine gets into transparent isolated part from the holding portion, again through applying the transparent isolated part of scattered hole outflow, when using the device, apply the liquid medicine in the scattered hole and can coat in the affected part of treating the phototherapy. Based on above-mentioned design and application process, compare in prior art, must coat earlier then implement phototherapy, this device can add the liquid medicine at any time in the use, and the cooperation phototherapy effect can realize better treatment. In addition, the design of isolation layer can avoid liquid medicine and first phototherapy module to contact, avoids polluting the base member for use experience is better.
Further, this technical scheme still carries out the optimal design to the inner structure of transparent isolation portion, specifically, separates the first cavity for the overflow that is located both ends and looses the chamber and be located two overflow scattered intracavity apply scattered chamber. The design of the overflow dispersion cavity can play a primary role in drainage dispersion on the liquid medicine so as to ensure that the liquid medicine can cover the dispersion cavity to the maximum extent and further uniformly overflow the dispersion holes. Preferably, the technical scheme further optimizes the design of the overflow dispersion cavity, namely: dividing the overflow dispersion cavity into: the liquid guiding part is communicated with the accommodating part and is used for guiding liquid; and a diffuser portion communicating with the liquid-introducing portion, the diffuser portion having a diameter larger than a diameter of the liquid-introducing portion.
Furthermore, the technical scheme is that a leakage-proof area is arranged on one side, far away from the base body, of the transparent isolation part, so that transition diffusion when liquid medicine overflows the spreading holes is prevented to the maximum extent, and the cleaning effect in the use process is guaranteed.
Further, this technical scheme still carries out the optimal design to the structure of first cavity, specifically, first phototherapy module with form first space between the circumference lateral wall of first cavity to be equipped with annular elastic expansion part in first space.
Drawings
Other features, objects and advantages of the present application will become more apparent upon reading of the following detailed description of non-limiting embodiments thereof, made with reference to the accompanying drawings in which:
fig. 1 is a schematic structural diagram of a phototherapy device for alleviating vitiligo symptoms.
FIG. 2 is a schematic view of a phototherapy apparatus for alleviating vitiligo symptoms (dosing);
FIG. 3 is a schematic view of a transparent spacer;
FIG. 4 is a schematic top view of a transparent partition;
FIG. 5 is a schematic top view of a transparent partition (elastic compression part);
FIG. 6 is a schematic view of a phototherapy apparatus for alleviating vitiligo symptoms (leak proof edge);
fig. 7 is a schematic view of a phototherapy apparatus for alleviating vitiligo symptoms (elastic expansion part);
fig. 8 is a schematic structural view (lead) of a phototherapy device for alleviating vitiligo symptoms;
fig. 9 is a schematic structural view of a phototherapy apparatus for alleviating vitiligo symptoms (elastic marking ring and phototherapy unit).
Detailed Description
The present application will be described in further detail with reference to the following drawings and examples. It is to be understood that the specific embodiments described herein are merely illustrative of the relevant invention and not restrictive of the invention. It should be noted that, for convenience of description, only the portions related to the present invention are shown in the drawings.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present application will be described in detail below with reference to the embodiments with reference to the attached drawings.
The first embodiment is as follows:
please refer to fig. 1, which is a schematic structural diagram of a phototherapy device for alleviating vitiligo symptoms.
The phototherapy device for alleviating vitiligo symptoms comprises:
a base body 10;
a first cavity 20 is formed on a first side of the substrate 10, and a first phototherapy module 21 is formed in the first cavity 20;
two second cavities 30 are further formed on the first side of the substrate 10, and the two second cavities 30 are distributed on two sides of the first cavity 20; the second cavity 30 is provided with accommodating parts 31 capable of accommodating liquid medicine, and transparent isolating parts 40 respectively communicated with the accommodating parts 31 are arranged between the two accommodating parts 31;
the transparent isolation part 40 is laid on the first phototherapy module 21; and the transparent isolation part 40 is provided with a dispersion hole 41 at one side relatively far away from the first phototherapy module 21.
Wherein:
with the extensive research of free radicals in medicine, the successful culture of melanocytes in vitro and the development of enzyme and enzyme activity detection technology, some enzymes in the free radical defense system of leucoderma patients are discoveredDecreased activity, intraepidermal H2O2Aggregation, which causes oxidative stress, interferes with biopterin circulation, inhibits some enzyme activities, directly or indirectly damages melanocytes, and clinically develops depigmenting white spots.
Red light therapy is the treatment of filtering most of red light, mainly in the red band, and its biological action is mainly photochemical action, not thermal action. The foreign scholars believe that the absorption maximum in the red region is mitochondria, and after red light irradiation, the catalase activity of mitochondria can be increased. Catalase (CAT), an enzyme that catalyzes the decomposition of hydrogen peroxide into oxygen and water, reduces the level of H2O2 in the epidermis, increases enzyme activity, and avoids damage to melanocytes.
In order to conveniently realize phototherapy for a patient area, the embodiment specifically provides a specific structure of a phototherapy device for relieving leucoderma symptoms.
Wherein:
the substrate 10 may be made of a flexible material, and a first cavity is disposed on one side of the substrate, as shown in fig. 1, a length direction of the substrate is a first direction, and a width direction of the substrate is a second direction. A first phototherapy module 21 is formed in the first cavity. Optionally, the base 10 has a strip structure so as to enable the first phototherapy module 21 thereon to be attached to the affected part of the patient. Preferably, the first cavity is circular or rectangular in shape.
Two second cavities 30 are further formed on the first side of the substrate 10, and the two second cavities 30 are distributed on two sides of the first cavity 20. As shown in fig. 1, optionally, the second cavity extends in a second direction. Preferably, the second cavity is a cylindrical structure.
And an accommodating part 31 disposed in the second cavity, wherein optionally, the accommodating part 31 is a columnar structure and extends along a second direction, and the accommodating part is disposed across the second cavity. The liquid medicine storage device is characterized in that a containing cavity is arranged in the containing part, the containing cavity is of a sealing structure and can contain liquid medicine, and an outlet is formed in the bottom of the containing cavity. Optionally, a one-way valve is arranged at an outlet of the accommodating cavity, so that the amount of the liquid medicine entering the transparent isolating part can be controlled conveniently.
And the transparent isolating part is arranged between the outlets of the two accommodating cavities. The inside transparent isolation chamber that is equipped with of transparent isolation portion, the both ends of transparent isolation portion are linked together with holding the chamber export respectively, so keep apart the intracavity and hold the chamber and be linked together.
In the specific application scene, just correspond the patient affected part with first phototherapy module earlier to make the mutual lock in both ends of base member, concrete lock mode is not limited, if: buttons, or magnetic buttons, or magic tapes. The extrusion holds the chamber (if, also can start the solenoid valve), holds in the liquid medicine entering transparent isolation portion of intracavity to spill and leave relatively on transparent isolation layer via spreading the hole on one side of base member, apply the downthehole liquid medicine of loosing and can coat in the affected part of treating the phototherapy.
Based on above-mentioned design and application process, compare in prior art, must coat earlier then implement phototherapy, this device can add the liquid medicine at any time in the use, and the cooperation phototherapy effect can realize better treatment. In addition, the design of isolation portion can avoid liquid medicine and first phototherapy module to contact, avoids polluting the base member for use experience is better.
Optionally, an outlet is arranged on the accommodating part 31 and a dosing part 32 is arranged at the outlet; the outlet of the quantitative administration part 32 is connected with the inlet of a transparent isolation part 40; the receiving portion 31 is further provided with an injection port exposed outside the second cavity 30. Specifically, the dosing section 32 may be a solenoid valve. Specifically, in order to facilitate the filling of the liquid medicine into the accommodating portion 31, the accommodating portion 31 is further provided with an injection port exposed outside the second cavity 30, and as shown in fig. 2, the injection port is exposed on the second side of the base.
Example two:
different from the first embodiment, the transparent isolation portion is specifically and optimally designed in the present embodiment.
The transparent partition 40 is provided with a first cavity 42 therein.
The first cavity 42 includes: the overflow and scattering cavity 421 is arranged at two ends of the transparent isolation part 40 and can be communicated with the containing part 31, and the spreading cavity 422 is positioned in the middle of the overflow and scattering cavity 421 and is communicated with the overflow and scattering cavity 421; the side of the scattering cavity 422 relatively far away from the first phototherapy module 21 is provided with a scattering hole 41.
In fig. 3, the first cavity is divided into a scattering cavity at both ends and a scattering cavity in the scattering cavities. The design of the overflow dispersion cavity can play a primary role in drainage dispersion on the liquid medicine so as to ensure that the liquid medicine can cover the dispersion cavity to the maximum extent and further uniformly overflow the dispersion holes.
In particular, the scattering cavity is preferably circular or rectangular to accommodate the shape of the first phototherapy module.
Preferably, referring to fig. 4, the effusion cell 421 includes: a liquid introducing portion 423 communicating with the housing portion 31 and a diffusing portion 424 communicating with the liquid introducing portion 423; the diameter of the diffuser portion 424 is larger than the diameter of the liquid introducing portion 423.
This technical scheme still to overflowing scattered chamber further optimal design, promptly: dividing the overflow dispersion cavity into: the liquid guiding part is communicated with the accommodating part and is used for guiding liquid; and a diffuser portion communicating with the liquid-introducing portion. The liquid medicine enters the diffusion part from the liquid guiding part, and the diameter of the diffusion part is larger than that of the liquid guiding part, so that the liquid medicine entering the diffusion part can be fully diffused in the diffusion part, the liquid medicine can uniformly enter the spreading cavity, and the liquid medicine can uniformly overflow and spread out of the spreading hole.
Specifically, the liquid introducing portion is tapered in shape for gradually diffusing the liquid medicine.
Specifically, the diffusion part is in a semicircular structure, one end of the diffusion part is connected with the end with the larger diameter of the liquid guiding part, and the diffusion part is used for receiving the liquid medicine guided by the liquid guiding part and diffusing the liquid medicine to the maximum extent so as to enter the diffusion cavity.
Optionally, an elastic compression part 425 is arranged at the bottom in the scattering cavity 422; and the elastic compression part 425 is hollow inside and communicates with the diffuser part 424.
Referring to fig. 5, based on the above design, the chemical liquid enters the diffusion portion from the liquid leading portion, and then enters the elastic expansion portion.
On one hand, the elastic expansion part is designed to facilitate the buffer storage of the liquid medicine and avoid the occurrence of the situation of excessive liquid medicine released at a time; on the other hand, under the self-gravity of the elastic expansion part, it can help the discharge of the liquid medicine and can be uniformly spread on the affected part of the patient under the pressure of the elastic expansion part.
Optionally, the elastic expansion part is an expansion joint structure with a columnar structure, and the interior of the elastic expansion part is hollow and is communicated with the diffusion part.
Example three:
the region on the same side of the transparent isolation part 40 with the scattering hole 41 is also provided with a leakage-proof region which is annularly arranged at the outer circumference of the scattering cavity 422; the leakage preventing section includes: the leakage-proof edge 50 is arranged around the spreading cavity 422.
Referring to fig. 6, specifically, the leakage-proof edge is in an annular structure and is uniformly distributed along the circumferential direction of the spreading hole, specifically, the leakage-proof edge 50 is made of the same material as the spreading cavity 422, such as a silica gel material, on the side facing the spreading cavity 422; the leak protection is equipped with adsorbed layer 51 along 50 one sides of keeping away from on the border of bottom of spreading the chamber 422, if: a cotton layer or a nonwoven layer.
Optionally, the longitudinal section of the leakage-proof edge is in a trapezoidal structure.
In the specific application scene, the leakage-proof will not influence its use along the contact of inner wall and liquid medicine, however, if the liquid medicine is scattered outward, the adsorbed layer can be to its preliminary absorption, prevents to spill over to the outside that the base member covered.
Example four:
a first space is formed between the first phototherapy module 21 and the circumferential side wall of the first cavity 20; an elastic expansion part 60 which is arranged annularly is arranged in the first space; the base body 10 is provided with an adjusting part 70 for adjusting the elastic expansion part 60 and a lead part 80 for connecting the adjusting part 70 and the elastic expansion part 60; the adjustment part 70 is rotated to drive the lead part 80 to pull the elastic expansion part 60 to contract or expand.
Referring to fig. 7, the thickness of the first phototherapy module is lower than the height of the first cavity, so a first space is formed between the first phototherapy module and the inner wall of the first cavity.
The elastic telescopic part is of an annular structure, and the outer edge with the larger diameter is connected with the side wall of the first cavity.
In fig. 7, the base body further includes a lead portion having one end connected to the elastic expansion portion and an adjustment portion connected to the other end of the lead portion.
When the regulating portion 70 is not rotated, the regulating portion is maintained in an initial state, and the length of the end of the lead portion connected to the regulating portion wound around the regulating portion is the largest, that is: the length that the lead wire portion is connected on the elastic expansion portion is the shortest, and at this moment, the elastic expansion portion contracts to furthest, and the region that the inner fringe of elastic expansion portion was exposed is the biggest, promptly: the second space is largest and the area of the first phototherapy module exposed through the second space is also largest.
When the regulating part 70 is rotated, the length of the end of the lead part connected with the regulating part wound on the regulating part begins to change, namely: the length crescent of lead wire portion connection on the elastic expansion portion, at this moment, the elastic expansion portion progressively expands, and the region that the inner fringe of elastic expansion portion exposed reduces gradually, promptly: the second space is gradually reduced, and the area of the first phototherapy module exposed through the second space is also gradually reduced.
Specifically, referring to fig. 8, a plurality of first lead channels 61 are disposed in an annular array on the elastic expansion portion 60; the base body 10 is provided with a second lead channel 11 which is arranged corresponding to the first lead channel 61 and is communicated with the first lead channel; the other end of the second lead channel 11 is exposed at the second side of the substrate 10; the lead portion 80 includes: a lead wire 81 which enters the first lead passage 61 from the second lead passage 11 and is connected to the inner edge of the elastic regulation portion 70; the adjusting portion 70 includes: and a retracting mechanism 71 located on the second side of the base body 10 for retracting the leads 81 in the second lead passage 11.
A specific embodiment of the lead portion is given in fig. 8, namely: and a lead 81.
The adjusting part can be a retraction mechanism, such as a reel.
Preferably, referring to fig. 9, the first phototherapy module 21 includes: at least one phototherapy unit 211 concentrically arranged. The central phototherapy unit is of a circular structure; the phototherapy units outside the central phototherapy unit are elliptical rings, and may be one or two or three or four or five.
An elastic marking ring 62 is arranged between the annular inner edges of the elastic telescopic parts 60; a detection sensor 22 for detecting the marking ring 62 is arranged between two adjacent phototherapy units 211; further comprising: a control module configured to drive the phototherapy unit 211 corresponding to the marker ring 62 to be turned off when the detection sensor 22 detects the marker ring 62.
Optionally, the inside of the marking ring is embedded with metal marking balls distributed in an annular array in the marking ring, and accordingly, the detection sensor can be a miniature inductive proximity switch. The inductive proximity switch comprises: the circuit comprises an oscillator, a switching circuit and an amplifying output circuit. The oscillator generates an alternating magnetic field. When the marker ring approaches this alternating magnetic field and reaches an induction distance, eddy currents are generated within the metal marker sphere, causing the oscillation to decay, and thus cease. The oscillation and stop variation of the oscillator is processed by the post-stage amplifying circuit and converted into a switching signal, and the control module is triggered to drive the phototherapy unit 211 corresponding to the mark ring 62 to be closed.
Referring to fig. 9, the inner edge of the elastic expansion portion 60 with a smaller diameter is provided with an elastic marking ring 62, which contracts or expands with the contraction or expansion of the elastic expansion portion.
Referring to fig. 9, a detection sensor 22 for detecting the marking ring 62 is disposed between two adjacent phototherapy units 211; specifically, three annular phototherapy units are provided in fig. 9, and at least two detection sensors 22 distributed in an annular array are provided between two adjacent phototherapy units. Specifically, three annular phototherapy units include: a circular first phototherapy unit 211a located at the center, a third phototherapy unit 211c located at the outermost ring, and 211b located between the first phototherapy unit 211a and the third phototherapy unit 211 c.
The first detection sensor between the first phototherapy unit 211a and the second phototherapy unit 211b is 22 b.
The second detection sensor between the second phototherapy unit 211b and the third phototherapy unit 211c is 22c
A control module configured to drive the phototherapy unit 211 corresponding to the marker ring 62 to be turned off when the detection sensor 22 detects the marker ring 62.
The control module is provided with a corresponding relation between the detection sensor and the phototherapy unit, such as:
the second phototherapy unit 211b corresponds to the first detection sensor 22 b.
The third phototherapy unit 211c corresponds to the second detection sensor 22 c.
When the first detection sensor 22b detects the marker ring 62, it indicates that: the edge of the elastic telescopic part reaches the position of the first detector, at the moment, the elastic telescopic part shields the second phototherapy unit, and at the moment, the second phototherapy module and the third phototherapy unit are closed.
When the second detection sensor 22c detects the marker ring 62, it indicates that: the edge of the elastic expansion part reaches the position of the second detector, at the moment, the elastic expansion part shields the third phototherapy unit, and at the moment, the third phototherapy unit is closed.
By analogy, when the number of the phototherapy units is N, the number of the detection sensors is N-1, specifically, the corresponding relation between the detection sensors N-1 and the phototherapy units N is set, and the corresponding relation is stored in the control module.
When the detection sensor N-1 detects that all the marking rings exist, the control module closes the phototherapy units except the phototherapy unit N.
Based on above-mentioned design, control module can close the phototherapy unit who is sheltered from correspondingly according to the region that elastic stretching portion sheltered from, avoids the energy waste, increases the use scene of this device.
The above description is only a preferred embodiment of the application and is illustrative of the principles of the technology employed. It will be appreciated by a person skilled in the art that the scope of the invention as referred to in the present application is not limited to the embodiments with a specific combination of the above-mentioned features, but also covers other embodiments with any combination of the above-mentioned features or their equivalents without departing from the inventive concept. For example, the above features may be replaced with (but not limited to) features having similar functions disclosed in the present application.
Claims (10)
1. A phototherapy device for alleviating vitiligo symptoms is characterized in that,
the method comprises the following steps: a base (10);
a first cavity (20) is formed on the first side of the substrate (10), and a first phototherapy module (21) is formed in the first cavity (20);
two second cavities (30) are also formed on the first side of the base body (10), and the two second cavities (30) are distributed on two sides of the first cavity (20); the second cavity (30) is provided with accommodating parts (31) capable of accommodating liquid medicine, and transparent isolating parts (40) respectively communicated with the accommodating parts (31) are arranged between the two accommodating parts (31);
the transparent isolation part (40) is laid on the first phototherapy module (21); and one side of the transparent isolation part (40) relatively far away from the first phototherapy module (21) is provided with an applying and scattering hole (41).
2. A phototherapy device for alleviating the symptoms of vitiligo as set forth in claim 1, wherein:
an outlet is arranged on the accommodating part (31), and a quantitative dosing part (32) is arranged at the outlet;
the outlet of the quantitative dosing part (32) is connected with the inlet of a transparent isolation part (40);
the accommodating part (31) is also provided with an injection port exposed outside the second cavity (30).
3. A phototherapy device for alleviating the symptoms of vitiligo as claimed in claim 1 or 2, wherein:
a first cavity (42) is arranged in the transparent isolating part (40);
the first cavity (42) comprises: the overflow and dispersion cavities (421) are arranged at two ends of the transparent isolation part (40) and can be communicated with the containing part (31), and the dispersion cavities (422) are positioned in the middle of the overflow and dispersion cavities (421) and are communicated with the overflow and dispersion cavities (421);
one side of the scattering cavity (422) relatively far away from the first phototherapy module (21) is provided with scattering holes (41).
4. A phototherapy device as defined in claim 3, for alleviating the symptoms of vitiligo, wherein:
the spill cavity (421) comprises: a liquid introduction part (423) communicating with the housing part (31), and a diffusion part (424) communicating with the liquid introduction part (423);
the diameter of the diffuser portion (424) is larger than the diameter of the liquid guide portion (423).
5. A phototherapy device as defined in claim 4, for alleviating the symptoms of vitiligo, wherein:
an elastic compression part (425) is arranged at the bottom in the spreading cavity (422); and the elastic compression part (425) is hollow inside and communicated with the diffusion part (424).
6. A phototherapy device for alleviating the symptoms of vitiligo as claimed in claim 1 or 2, wherein:
the region on the same side of the transparent isolation part (40) and the scattering hole (41) is also provided with a leakage-proof region which is annularly arranged on the outer circumference of the scattering cavity (422);
the leakage preventing section includes: the leakage-proof edge (50) is annularly arranged on the circumferential direction of the spreading cavity (422), and one side, facing the spreading cavity (422), of the leakage-proof edge (50) is made of the same material as the spreading cavity (422); an adsorption layer (51) is arranged on one side, far away from the spreading cavity (422), of the edge of the bottom of the leakage-proof edge (50).
7. A phototherapy device for alleviating the symptoms of vitiligo as claimed in claim 1 or 2, wherein:
a first space is formed between the first phototherapy module (21) and a circumferential side wall of the first cavity (20);
an elastic expansion part (60) which is arranged annularly is arranged in the first space;
the base body (10) is provided with an adjusting part (70) for adjusting the elastic expansion part (60) and a lead part (80) for connecting the adjusting part (70) and the elastic expansion part (60);
the adjusting part (70) is rotated to drive the lead part (80) to pull the elastic expansion part (60) to contract or expand.
8. A phototherapy device as defined in claim 7, for alleviating the symptoms of vitiligo, wherein:
a plurality of first lead channels (61) are arranged on the elastic expansion part (60) in an annular array;
the base body (10) is provided with a second lead channel (11) which is arranged corresponding to the first lead channel (61) and is communicated with the first lead channel; the other end of the second lead channel (11) is exposed at the second side of the base body (10);
the lead part (80) includes: a lead wire (81) which enters the first lead passage (61) from the second lead passage (11) and is connected with the inner edge of the elastic adjusting part (70);
the adjustment section (70) includes: and a retracting mechanism (71) positioned on the second side of the base body (10) and used for retracting each lead (81) in the second lead channel (11).
9. A phototherapy device as defined in claim 7, for alleviating the symptoms of vitiligo, wherein:
the first phototherapy module (21) comprises: at least one annular phototherapy unit (211) arranged concentrically.
10. A phototherapy device for alleviating the symptoms of vitiligo as set forth in claim 9, wherein:
an elastic marking ring (62) is arranged between the annular inner edges of the elastic telescopic parts (60);
a detection sensor (22) for detecting the marking ring (62) is arranged between two adjacent phototherapy units (211);
further comprising: a control module configured to drive the phototherapy unit (211) corresponding to the marker ring (62) to be turned off when the marker ring (62) is detected by the detection sensor (22).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111494379.2A CN113975653B (en) | 2021-12-08 | 2021-12-08 | Phototherapy device for alleviating vitiligo symptoms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111494379.2A CN113975653B (en) | 2021-12-08 | 2021-12-08 | Phototherapy device for alleviating vitiligo symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113975653A true CN113975653A (en) | 2022-01-28 |
| CN113975653B CN113975653B (en) | 2024-01-26 |
Family
ID=79733523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111494379.2A Active CN113975653B (en) | 2021-12-08 | 2021-12-08 | Phototherapy device for alleviating vitiligo symptoms |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113975653B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070071801A1 (en) * | 2005-09-26 | 2007-03-29 | Kelly Jack P | Patch for treating symptoms of a skin abscess |
| US20160351038A1 (en) * | 2015-05-29 | 2016-12-01 | Midwest Business Associates, Inc. | System for medical device software alert hierarchy management |
| JP2017006347A (en) * | 2015-06-22 | 2017-01-12 | コニカミノルタ株式会社 | Optical treatment apparatus |
| JP2017006348A (en) * | 2015-06-22 | 2017-01-12 | コニカミノルタ株式会社 | Optical treatment apparatus |
| US20170225006A1 (en) * | 2016-02-09 | 2017-08-10 | Evan R. Anderson | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
| KR102079818B1 (en) * | 2019-08-29 | 2020-02-20 | 주식회사 이스텍코리아 | drug infusion mothod and device of skin by laser |
| CN111481424A (en) * | 2019-11-29 | 2020-08-04 | 焦在华 | Equipment for promoting drug effect absorption through light irradiation |
| CN111840809A (en) * | 2020-07-22 | 2020-10-30 | 固安翌光科技有限公司 | Optical medical device |
| CN212547986U (en) * | 2020-04-02 | 2021-02-19 | 北京翌光科技有限公司 | Wearable phototherapy wound device and wound subassembly |
| US20210113852A1 (en) * | 2019-10-21 | 2021-04-22 | Percy Luu | Methods and apparatus for phototherapy |
| CN213912001U (en) * | 2020-10-27 | 2021-08-10 | 上海市皮肤病医院 | Vitiligo traditional chinese medicine illumination machine convenient to carry |
-
2021
- 2021-12-08 CN CN202111494379.2A patent/CN113975653B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070071801A1 (en) * | 2005-09-26 | 2007-03-29 | Kelly Jack P | Patch for treating symptoms of a skin abscess |
| US20160351038A1 (en) * | 2015-05-29 | 2016-12-01 | Midwest Business Associates, Inc. | System for medical device software alert hierarchy management |
| JP2017006347A (en) * | 2015-06-22 | 2017-01-12 | コニカミノルタ株式会社 | Optical treatment apparatus |
| JP2017006348A (en) * | 2015-06-22 | 2017-01-12 | コニカミノルタ株式会社 | Optical treatment apparatus |
| US20170225006A1 (en) * | 2016-02-09 | 2017-08-10 | Evan R. Anderson | Methods, compositions and apparatuses for treating psoriasis by phototherapy |
| CN109310527A (en) * | 2016-02-09 | 2019-02-05 | 鲁玛治疗公司 | For treating psoriasic method, composition and equipment by light therapy |
| KR102079818B1 (en) * | 2019-08-29 | 2020-02-20 | 주식회사 이스텍코리아 | drug infusion mothod and device of skin by laser |
| US20210113852A1 (en) * | 2019-10-21 | 2021-04-22 | Percy Luu | Methods and apparatus for phototherapy |
| CN111481424A (en) * | 2019-11-29 | 2020-08-04 | 焦在华 | Equipment for promoting drug effect absorption through light irradiation |
| CN212547986U (en) * | 2020-04-02 | 2021-02-19 | 北京翌光科技有限公司 | Wearable phototherapy wound device and wound subassembly |
| CN111840809A (en) * | 2020-07-22 | 2020-10-30 | 固安翌光科技有限公司 | Optical medical device |
| CN213912001U (en) * | 2020-10-27 | 2021-08-10 | 上海市皮肤病医院 | Vitiligo traditional chinese medicine illumination machine convenient to carry |
Non-Patent Citations (1)
| Title |
|---|
| 于潮: "白癜风的光疗法", 中国激光医学杂志, no. 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113975653B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI684468B (en) | Apparatus for wound therapy | |
| CN111050711B (en) | Anti-deformation wound treatment devices and related methods of use | |
| US10507311B2 (en) | Wound care method and system with one or both of vacuum-light therapy and thermally augmented oxygenation | |
| CN111065363A (en) | Medical dressing | |
| US11559622B2 (en) | Deformation resistant wound therapy apparatus and related methods of use | |
| KR101597169B1 (en) | Mask devices for facial treatment | |
| US20180008837A1 (en) | Light therapy delivery devices and methods for the female genitalia and areas proximal thereto | |
| WO2013187572A1 (en) | Self-injection mechanism for use on skin | |
| KR101200669B1 (en) | The self injection-tool for skin | |
| CA2734684A1 (en) | Hyperbaric dressing and method | |
| TW201909937A (en) | Wound boost therapy | |
| CN101940817B (en) | Light-medicine-combined treatment device for skin ulcers | |
| CN113975653A (en) | Phototherapy device for relieving leucoderma symptoms | |
| WO2021035222A3 (en) | Apparatus for systemic human enhancement from administration of frequency therapy including enhanced stem cell and genetic therapy | |
| CN101284157A (en) | Transdermal drug delivery device | |
| CN106730097A (en) | A kind of hollow negative pressure drainage treatment system of alternating that hydrotherapy is circulated for surface of a wound debridement | |
| CN201871130U (en) | Light and medicine combined skin ulcer treatment device | |
| TW201330897A (en) | Photostimulation method and kit with agonist agent | |
| CN212593032U (en) | Portable chronic wound surface hyperbaric oxygen therapeutic instrument | |
| CN215652540U (en) | Three oxygen therapy limbs treatment bag | |
| KR101384700B1 (en) | Triple endorectal ballooning system | |
| JP2011161222A (en) | Optical wound treatment device | |
| TWI615163B (en) | Closed-wound drainage device | |
| CN210673553U (en) | Breathable self-heating navel paste | |
| CN220938282U (en) | Medicine soaking device for cornea crosslinking operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |